Cytokine and chemokine profiles in fibromyalgia, rheumatoid arthritis and systemic lupus erythematosus: A potentially useful tool in differential diagnosis

Rheumatology International

Volumn 35, Issue 6, 2015, Pages 991-996

  Wallace, Daniel J ^a   Gavin, Igor M ^b,c   Karpenko, Oleksly ^b   Barkhordar, Farnaz ^b   Gillis, Bruce S ^b,d  

^a Wallace Rheumatic Diseases Study Center   (United States)

^b EpicGenetics   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d UNIVERSITY OF ILLINOIS   (United States)

Author keywords

Chemokines; Cytokines; Fibromyalgia; Peripheral blood mononuclear cells; Phytohemagglutinin; Rheumatoid arthritis; Systemic lupus erythematosus

Indexed keywords

INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; AUTACOID; BIOLOGICAL MARKER; CHEMOKINE; CYTOKINE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST ACCURACY STUDY; DIFFERENTIAL DIAGNOSIS; FEMALE; FIBROMYALGIA; HUMAN; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHYSICAL EXAMINATION; PREDICTIVE VALUE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY; SYSTEMIC LUPUS ERYTHEMATOSUS; ADOLESCENT; ARTHRITIS, RHEUMATOID; BLOOD; CASE CONTROL STUDY; CELL CULTURE; COMPARATIVE STUDY; IMMUNOLOGY; LUPUS ERYTHEMATOSUS, SYSTEMIC; METABOLISM; MIDDLE AGED; MONONUCLEAR CELL; STATISTICAL MODEL; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ARTHRITIS, RHEUMATOID; BIOMARKERS; CASE-CONTROL STUDIES; CELLS, CULTURED; CHEMOKINES; CYTOKINES; DIAGNOSIS, DIFFERENTIAL; FEMALE; FIBROMYALGIA; HUMANS; INFLAMMATION MEDIATORS; LEUKOCYTES, MONONUCLEAR; LOGISTIC MODELS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; YOUNG ADULT;

EID: 84939417895     PISSN: 01728172     EISSN: 1437160X     Source Type: Journal    
DOI: 10.1007/s00296-014-3172-2     Document Type: Article

References (22)

1. Wallace DJ, Schwartz E, Chi-Lin H, Peter JB (1995) The ‘rule out lupus’ rheumatology consultation: clinical outcomes and perspectives. J Clin Rheumatol 1(3):158–164
2. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL et al (1990) The American College of Rheumatology 1990 criteria for the classification of fibromyalgia, report of the multicenter criteria committee. Arthritis Rheum 33:160–172
3. Clauw DJ, Fibromyalgia A (2014) Clinical review. JAMA 311:1547–1555
4. Chandran A, Schaefer C, Ryan K, Baik R, Mc Nett M, Zlateva G (2012) The comparative economic burden of mild, moderate, and severe fibromyalgia: results from a retrospective chart review and cross-sectional survey of working-age US adults. J Manag Care Pharm 18:415–426
5. Curtis JR, n Mil AH, Knevel R, Huizinga TW, Haney DJ, Shen Y et al (2012) Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activity. Arthritis Care Res (Hoboken) 64:1794–1803
6. Kalunian KC, Chatham WW, Massarotti EM, Reyes-Thomas J, Harris C, Furie RA (2012) Measurement of cell-bound complement activation products enhances diagnosic performance in systemic lupus erythematosus. Arthritis Rheum 64(12):4040–4047. doi:10.1002/art.34669
7. Behm FG, Gavin IM, Karpenko O, Lindgren V, Gaitonde S, Gashkoff PA, Gillis BS (2012) Unique immunologic patterns in fibromyalgia. BMC Clin Pathol 12:25. doi:10.1186/1472-6890-12-25
8. Middleton GD, McFarlin JE, Lipsky PE (1994) The prevalence and clinical impact of fibromyalgia in systemic lupus erythematosus. Arthritis Rheum 37:1181–1188
9. Morand EF, Miller MH, Whittingham S, Littlejohn GO (1994) Fibromyalgia syndrome and disease activity in systemic lupus erythematosus. Lupus 3:187–191
10. Vitali C, Tavoni A, Neri R, Castrogiavanni P, Bombardieri S, Pasero G et al (1989) Fibromyalgia features in patients with primary Sjogren’s syndrome. Evidence of a relationship with psychological depression. Scand J Rheumatol 18:21–27
11. Tishler M, Barak Y, Paran D, Yaron M (1997) Sleep disturbances, fibromyalgia and primary Sjogren’s syndrome. Clin Exp Rheumatol 15:71–74
12. Wolfe F, Michaud K (2004) Severe rheumatoid arthritis (RA), worse outcomes, comorbid illness, and sociodemographic disadvantage characterize RA patients with fibromyalgia. J Rheumatol 31:695–700
13. Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725
14. Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO III (2010) 2010 rheumatoid arthritis classification criteria. An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 62:2569–2581
15. R Core Team (2013) A language and environment for statistical computing. Vienna, Austria, http://www.R-project.org/
16. Harrell FE (2013) RMS: regression modeling strategies. http://CRAN-R-project.org/package=rms
17. Wallace DJ, Linker-Israeli M, Hallegua D, Silverman S, Silver D, Weisman MH (2001) Cytokines play an aetiopathogenetic role in fibromyalgia: a hypothesis and pilot study. Rheumatology 40:743–749
18. Wallace DJ, Margolin K, Waller P (1988) Fibromyalgia and interleukin therapy for malignancy. Ann Intern Med 108:909
19. Crofford LJ, Pillemer SR, Kalogeras KT, Cash JM, Michelson D, Kling MA et al (1994) Hypothalamic-pituitary-adrenal axis pertubations in patients with fibromyalgia. Arthritis Rheum 37(11):1583–1592
20. Meeus M, Goubert D, De Backer F, Struyf F, Hermans L, Coppieters I et al (2013) Heart rate variability in patients with fibromyalgia and patients with chronic fatigue syndrome: a systemicatic review. Semin Arthritis Rheum 43(2):279–287. doi:10.1016/j.semarthrit.2013.03.004 (Epub 2013 Jul 6). Review
21. Watkins LR, Hutchinson MR, Rice KC, Maier SF (2009) The “toll” of opioid-induced glial activation: improving the clinical efficacy of opioids by targeting glia. Trends Pharmacol Sci 30(11):581–591. doi:10.1016/j.tips.2009.08.002 (Epub 2009 Sep 15)
22. Grondal G, Gunnarsson I, Ronnelid J, Rogberg S, Klareskog L, Lundberg I (2000) Cytokine production, serum levels and disease activity in systemic lupus ertythematosus. Clin Exp Rheumatol 18:565–570